Innate Pharma (IPHA) Short term Debt (2017 - 2025)
Innate Pharma (IPHA) has disclosed Short term Debt for 8 consecutive years, with $9.3 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Short term Debt fell 3.21% year-over-year to $9.3 million, compared with a TTM value of $9.3 million through Dec 2024, down 3.21%, and an annual FY2024 reading of $9.4 million, down 2.48% over the prior year.
- Short term Debt was $9.3 million for Q4 2024 at Innate Pharma, down from $9.6 million in the prior quarter.
- Across five years, Short term Debt topped out at $35.2 million in Q4 2021 and bottomed at $2.1 million in Q4 2022.
- Average Short term Debt over 5 years is $11.8 million, with a median of $9.3 million recorded in 2024.
- The sharpest move saw Short term Debt skyrocketed 1277.31% in 2021, then tumbled 93.9% in 2022.
- Year by year, Short term Debt stood at $2.6 million in 2020, then surged by 1277.31% to $35.2 million in 2021, then crashed by 93.9% to $2.1 million in 2022, then surged by 348.33% to $9.6 million in 2023, then decreased by 3.21% to $9.3 million in 2024.
- Business Quant data shows Short term Debt for IPHA at $9.3 million in Q4 2024, $9.6 million in Q4 2023, and $2.1 million in Q4 2022.